Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill; Catarina Raposo; Ariel Rechtman; Omri Zveik; Netta Levin; Esther Oiknine-Djian; Dana G. Wolf; Adi Vaknin-Dembinsky

doi:10.1002/ana.26343

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill, Catarina Raposo, Ariel Rechtman, Omri Zveik, Netta Levin, Esther Oiknine-Djian, Dana G. Wolf, Adi Vaknin-Dembinsky^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

Original language	English
Pages (from-to)	796-800
Number of pages	5
Journal	Annals of Neurology
Volume	91
Issue number	6
DOIs	https://doi.org/10.1002/ana.26343
State	Published - Jun 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ana.26343

Cite this

@article{1b147dd934c94317947111ed98789be1,

title = "Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab",

abstract = "The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.",

author = "Livnat Brill and Catarina Raposo and Ariel Rechtman and Omri Zveik and Netta Levin and Esther Oiknine-Djian and Wolf, {Dana G.} and Adi Vaknin-Dembinsky",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2022",

month = jun,

doi = "10.1002/ana.26343",

language = "אנגלית",

volume = "91",

pages = "796--800",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley & Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

AU - Brill, Livnat

AU - Raposo, Catarina

AU - Rechtman, Ariel

AU - Zveik, Omri

AU - Levin, Netta

AU - Oiknine-Djian, Esther

AU - Wolf, Dana G.

AU - Vaknin-Dembinsky, Adi

PY - 2022/6

Y1 - 2022/6

N2 - The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

AB - The introduction of a third-dose vaccination along with new variants of concern raises questions regarding serology and T-cell responses in patients with multiple sclerosis (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study was to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following a third vaccine dose. Following the third vaccine dose, patients who are low or nonresponders following initial vaccination did not increase antibody titers. In healthy controls and ocrelizumab-treated pwMS, cellular response decreased 6 months after initial vaccination and increased significantly after the third dose. ANN NEUROL 2022;91:796–800.

UR - http://www.scopus.com/inward/record.url?scp=85127001289&partnerID=8YFLogxK

U2 - 10.1002/ana.26343

DO - 10.1002/ana.26343

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35243687

AN - SCOPUS:85127001289

SN - 0364-5134

VL - 91

SP - 796

EP - 800

JO - Annals of Neurology

JF - Annals of Neurology

IS - 6

ER -

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this